Annual Report

The report describes ROVI's 11% increase in operating revenues to 141.8 million euros in 2009, driven by pharmaceutical products including Bemiparin. It also highlights the year's strategic manufacturing agreement with MSD and progress toward a seasonal and pandemic flu vaccine production centre. Its corporate social responsibility section reports more than 230,000 euros in environmental investments, while the workforce section reports 2,310 training hours and implementation of OHSAS 18001 across named group companies.